Standard Article

Xenotransplantation in Pharmaceutical Biotechnology


  1. Gregory J. Brunn1,2,
  2. Jeffrey L. Platt1,3

Published Online: 15 SEP 2006

DOI: 10.1002/3527600906.mcb.200400124

Reviews in Cell Biology and Molecular Medicine

Reviews in Cell Biology and Molecular Medicine

How to Cite

Brunn, G. J. and Platt, J. L. 2006. Xenotransplantation in Pharmaceutical Biotechnology. Reviews in Cell Biology and Molecular Medicine. .

Author Information

  1. 1

    Transplantation Biology Program, Mayo Clinic, Rochester, MN

  2. 2

    Department of Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN

  3. 3

    Departments of Surgery, Immunology and Pediatrics, Mayo Clinic, Rochester, MN

Publication History

  1. Published Online: 15 SEP 2006


For nearly a century, xenotransplantation has been seen as a potential curative approach to replacing the function of diseased or damaged organs. Until recently, however, the application of xenotransplantation has seemed only a remote possibility. Genetic engineering of large animals has allowed the ability to add genes and remove genes from lines of animals, which could provide an enduring source of tissues and organs for clinical application. Genetic engineering could address the immunologic, physiologic, and infectious barriers to xenotransplantation, and could expand the utility of xenotransplantation to provide a source of cells with defined expression of exogenous genes for treatment of human disease.


  • Accommodation;
  • Acute Vascular Rejection;
  • Genetic Engineering;
  • Humoral Immunity;
  • Hyperacute Rejection;
  • Xenotransplantation;
  • Zoonosis